DAWN
NASDAQ · Biotechnology
Day One Biopharmaceuticals I
$21.53
+0.04 (+0.19%)
Open$21.50
Previous Close$21.49
Day High$21.53
Day Low$21.49
52W High$21.53
52W Low$5.64
Volume—
Avg Volume1.59M
Market Cap2.22B
P/E Ratio—
EPS$-1.04
SectorBiotechnology
Analyst Ratings
Hold
13 analysts
Price Target
+161.4% upside
Current
$21.53
$21.53
Target
$56.28
$56.28
$41.40
$56.28 avg
$65.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 158.38M | 322.81M | 330.87M |
| Net Income | -107,457,204 | -68,873,512 | -86,473,457 |
| Profit Margin | -67.9% | -21.3% | -26.1% |
| EBITDA | -127,566,034 | -92,549,420 | -89,278,899 |
| Free Cash Flow | — | -81,242,335 | -91,466,852 |
| Rev Growth | — | +3.3% | -3.7% |
| Debt/Equity | — | 0.57 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |